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ABSTRACT
Context: The nitrobezoxadiazole derivative NBDHEX is a potent inhibitor of glutathione transferase P1-1
(GSTP1-1) endowed with outstanding anticancer activity in different tumor models.
Objective: To characterize by in vitro biochemical and in silico studies the NBDHEX analogues named
MC2752 and MC2753.
Materials and methods: Synthesis of MC2752 and MC2753, biochemical assays and in silico docking and
normal-mode analyses.
Results: The presence of a hydrophobic moiety in the side chain of MC2753 confers unique features to
this molecule. Unlike its parent drug NBDHEX, MC2753 does not require GSH to trigger the dissociation of
the complex between GSTP1-1 and TRAF2, and displays high stability towards the nucleophilic attack of
the tripeptide under physiological conditions.
Discussion and conclusion: MC2753 may represent a lead compound for the development of novel
GSTP1-1 inhibitors not affected in their anticancer action by fluctuations of cellular GSH levels, and charac-
terized by an increased half-life in vivo.
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Glutathione transferases (formerly glutathione S-transferases; GSTs;
EC 2.5.1.18) constitute one of the most important families of
detoxifying enzymes and are also involved in the development of
multidrug-resistance in tumors1. The ability of GSTs to promote
conjugation of the tripeptide glutathione (GSH) with a variety of
substrates leads to inactivation of various reactive compounds,
including some anticancer drugs. Moreover, tumor cell overexpres-
sion of the Pi-class isoform glutathione transferase P1-1 (GSTP1-1)
has been associated with inhibition of apoptosis through direct
interaction of this enzyme with the mitogen-activated protein kin-
ase (MAPK) named c-Jun-N-terminal Kinase 1 (JNK1), and the
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scaffold protein TNFa-receptor-associated-factor 2 (TRAF2). Therefore,
a new promising strategy for tumor treatment may be the use of
agents capable of inducing apoptosis by targeting GSTP1-11.
In a search for selective GST inhibitors, we identified the nitro-
benzoxadiazole (NBD) derivative NBDHEX (1), as a potent inhibitor
of GSTP1-12. This compound behaves as a mechanism-based
inhibitor of human GSTP1-1, by first being recognized as a sub-
strate, followed by conjugation to GSH, to form an intermediate
r-complex which binds very tightly (Kd¼ 109 M) to the protein,
with subsequent loss of both enzyme (GSH-conjugating) activity
and capability to form complexes with the partner proteins JNK1
and TRAF23–6. Compound 1 was found to exhibit remarkable pro-
apoptotic activity towards cultured tumor cells of different origin,
as well as therapeutic activity in some human tumor xenograft
models1,7,8. More recently, several analogs of 1 bearing variously
substituted alkyl chains or aryl moieties at the C4-sulfur atom
have been prepared with the aim of obtaining compounds
endowed with more favorable pharmaceutical and/or pharmaco-
logical properties9. Here we report the design and synthesis of
two novel derivatives of 1, namely compound 2 (MC2753), i.e. the
benzoic acid ester of 1, and compound 3 (MC2752), i.e. the acetic
acid ester of 1 (see Scheme 1). We focused our attention on 2
since the presence of a hydrophobic moiety in the side chain
changes the mode of interaction of the NBD derivative with the
target protein (i.e. GSTP1-1), and remarkably decreases its spontan-
eous reactivity towards GSH.
Materials and methods
Chemicals
Unless specified otherwise, all chemicals used throughout this
work were purchased from Sigma-Aldrich (St. Louis, MO). GS-NDB
was synthesised as previously described2.
Chemistry
Melting points were determined on a Buchi 530 melting point
apparatus (Flawil, Switzerland) and are uncorrected. 1H-NMR spec-
tra were recorded at 400MHz on a Bruker AC 400 spectrometer
(Billerica, MA); reporting chemical shifts in d (ppm) units relative to
the internal reference tetramethylsilane (Me4Si). All compounds
were routinely checked by TLC and 1H-NMR. TLC was performed
on aluminum-backed silica gel plates (Merck DC, Alufolien
Kieselgel 60 F254, Kenilworth, NJ) with spots visualized by UV light.
Yields of all reactions refer to the purified products. All chemicals
were of the highest purity. Mass spectra were recorded on an API-
TOF Mariner by Perspective Biosystem; samples were injected by
an Harvard pump using a flow rate of 5–10lL/min, infused in the
Electrospray system. Elemental analyses were performed by a PE
2400 (Perkin-Elmer, Waltham, MA) analyzer and have been used to
determine purity of the described compounds, which is >95%.
Analytical results are within ±0.40% of the theoretical values.
General procedure for the preparation of 2 and 3: Example:
6-((7 nitrobenzo[c][1,2,5]oxadiazol-4-yl)thio)hexyl benzoate (2)
A solution of benzoyl chloride (94.55mg, 0.078mL, 0.672mmol) in
dry DCM (2mL) was added dropwise at 0 C to a solution of 1
(100mg, 0.336mmol) and TEA (85.08mg, 0.117mL, 0.840mmol) in
dry DCM (3mL), and the resulting mixture was stirred at room
temperature for 22 h. The mixture was then diluted with 10mL of
DCM and washed with HCl 2 N (2 5mL), NaHCO3 saturated solu-
tion (3 5mL) and finally with brine (1 5mL). The organic phase
was dried over Na2SO4, filtered and evaporated under vacuum
providing a crude solid, which was purified by a silica gel flash
chromatography (SNAP 50, Biotage Isolera OneTM, Uppsala,
Sweden) using a linear gradient of AcOEt (5–30%) in Hexane to
give 2 as a pure yellow solid. Yield: 76%. M.p.: 84–85 C. 1H-NMR
(CDCl3) d 1.56–1.58 (m, 2H CH2CH2CH2CH2OCO), 1.60–1.67 (m, 2H,
CH2CH2CH2OCO), 1.80–1.84 (m, 2H, SCH2CH2), 1.86–1.93 (m, 2H,
CH2CH2OCO), 3.28–3.32 (t, 2H, SCH2), 4.35–4.38 (t, 2H, CH2OCO),
7.14–7.16 (d, 1H, CH benzoxadiazole ring), 7.44–7.47 (t, 2H, CH
benzene ring), 7.56–7.60 (t, 1H, CH benzene ring), 8.04–8.06 (d, 2H,
CH benzene ring), 8.40–8.42 (d, 1H, CH benzoxadiazole ring). 13C-
NMR (CDCl3) d 25.3, 28.4, 30.5, 30.8, 31.4, 64.5, 119.1, 124.4, 126.2,
128.4 (2C), 129.7 (2C), 130.1, 133.2, 135.6, 144.1, 143.9, 165.8 ppm.
Anal. (C19H19N3O5S) Calcd. (%): C, 56.85; H, 4.77; N, 10.47; S, 7.99.
Found (%): C, 56.15; H, 4.62; N, 10.59; S, 8.07. MS (ESI), m/z: 402
[MþH]þ. 3: Yield: 73%. M.p.: 57–58 C. 1H-NMR (CDCl3) d
1.41–1.48 (m, 2H CH2CH2CH2CH2OCO), 1.58–1.62 (m, 2H,
CH2CH2CH2OCO), 1.64–1.71 (m, 2H, SCH2CH2), 1.83–1.91 (m, 2H,
CH2CH2OCO), 2.05 (s, 3H, OCOCH3), 3.26–3.30 (t, 2H, SCH2),
4.06–4.09 (t, 2H, CH2OCO), 7.11–7.18 (d, 1H, CH benzoxadiazole
ring), 8.40–8.42 (d, 1H, CH benzoxadiazole ring). 13C-NMR (CDCl3) d
20.7, 25.3, 28.3, 28.9, 30.4, 30.9, 64.8, 119.1, 124.7, 126.4, 135.8,
143.6, 143.9, 170.1 ppm. Anal. (C14H17N3O5S) Calcd. (%): C, 49.55; H,
5.05; N, 12.38; S, 9.45. Found (%): C, 49.01; H, 4.94; N, 12.51; S,
9.59. MS (ESI), m/z: 340 [MþH]þ.
Evaluation of solubility and molar extinction coefficient (e) of
compounds 2 and 3
Each compound was first dissolved in DMSO, and then diluted in
a buffer (0.1 M potassium phosphate, 0.1mM EDTA, pH 6.5) sup-
plemented with different amounts of Triton X-100. The UV–visible
spectra of the obtained solutions were then recorded. Standard
solutions of both compounds were prepared in the above buffer
supplemented with 0.1% (v/v) Triton X-100, and the molar extinc-
tion coefficients were obtained by linear regression analysis of
plots of absorbance at 430 nm versus compound concentration.
Kinetic analysis
The enzymatic activity of GSTP1-1 (20 nM subunits) was spectro-
photometrically assayed at 340 nm (e¼ 9600 M1 cm1) and at
25 C, by measuring the rate of CDNB conjugation with GSH as a
function of time. The assay mixture contained 1mM GSH, and
1mM CDNB in 1mL of 0.1 M potassium phosphate buffer (pH 6.5)
containing 0.1mM EDTA and 0.1% (v/v) Triton X-100 (buffer A) or
in the same buffer lacking the detergent (buffer B). The inhibitory
efficacy of compounds 1, 2 and 3 was determined by recording
the activity of GSTP1-1 in the presence of various amounts of the
selected NBD derivative (0.01–40lM). The Kiapp values for each
compound were obtained by fitting the data points to a hyper-
bolic saturation curve, using GraphPad Prism 5 software (La Jolla,
CA). For multiple inhibition analysis, the GST activity was measured
in the presence of variable amounts of 2 (0.1–10lM) at different
fixed concentrations of compound 1 (0.2–10 lM).
Spectrophotometric analysis
The spontaneous reactivity of 1 and 2 with GSH was first deter-
mined by recording at 25 C the UV–visible spectrum of each com-
pound (20lM), dissolved in buffer A (pH 6.5), before and at
different times after the addition of GSH (1mM). The ability of
GSTP1-1 to stabilize the r-complex was evaluated by recording
the spectrum of these compounds before and after the addition
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of GSH (1mM) and a stoichiometric amount of GSTP1-1 (20lM).
The same experiments were then repeated at 37 C and pH 7.4 to
mimic the physiological environment in terms of pH and tempera-
ture. All spectra were recorded against buffer A.
Spectrofluorometric analysis
The emission spectra of both 1 and 2 (4 lM in buffer A, pH 6.5)
were recorded at 25 C, using the following conditions:
kexc¼ 405 nm, kem¼ 450–700 nm; slits, 5–10 nm, with a 455 nm
cutoff filter. Spectra were also recorded upon addition of variable
amounts of GSTP1-1 (1–20lM) and 1mM GSH.
The interaction of 2 with GSTP1-1 was also analyzed at 25 C
and pH 6.5 by following the quenching of the intrinsic fluorescence
of the protein (kexc¼ 280nm and kem¼ 300–450nm; slits 5–5nm).
Spectra were measured before and after the addition of 2 (20lM) to
GSTP1-1 (4lM) dissolved in buffer B, or buffer B containing 1mM
GSH. Fluorescence spectra were recorded in a single photon count-
ing spectrofluorometer (Fluoromax-4, Horiba, Irvine, CA) and data
were corrected both for dilution and for inner filter effects.
ELISA for protein–protein interaction analysis
The complex formation between TRAF2 and GSTP1-1 was studied
as previously described6. Briefly, 200 lL of His-tagged TRAF2 C-ter-
minal domain (0.005 lM in 20mM Tris–HCl, pH 7.6 containing
150mM NaCl and 10% glycerol) was added to each well of a 96-
well His-Sorb plate (Qiagen, Hilden, Germany) and incubated over-
night at 4 C on a rocking platform. Afterward, wells were washed
with PBS and incubated for 30min with GSTP1-1 (concentration
range from 0.1 to 8lM) in 10mM potassium phosphate buffer, pH
7.0, containing 0.1mM EDTA. Incubation with GSTP1-1 was also per-
formed in the presence of 1 (8 lM) or 2 (20 lM), both in the
absence and presence of GSH (1mM). At the end of incubation, the
wells were washed with PBS and then filled with 200 lL of a mouse
anti-GSTP1-1 antibody for 2 h at room temperature. Subsequently,
wells were washed with PBS and incubated with an anti-mouse IgG
antibody for 45min at room temperature. The immunocomplexes
were detected by the addiction of 200 lL per well of the 1-Step-
Turbo TMB substrate solution (Pierce, Los Angeles, CA). The reaction
was stopped after 10min by the addition of 50 lL of 2 M H2SO4,
and the absorbance was measured at 450 nm. Data were analyzed
by fitting to Equation (1) where m is the percentage of the saturated
binding sites; [P]t and [L]t are the total concentrations of monomeric
GSTP1-1 and TRAF2, respectively10.
m ¼ 100
P½ tþ L½ tþKd 
ffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffiffi
P½ tþ L½ tþKd





Unless specified otherwise, experiments were repeated at least
three times, and results are presented as mean± SD.
Results
Chemistry
The ester derivatives 2 and 3 were obtained by an acylation reac-
tion of 1, prepared as reported previously9, with the appropriate
commercial acyl chloride under basic conditions as shown in
Scheme 1.
Chemical and physical properties of compounds 2 and 3
The aqueous solubility of compounds 2 and 3 is lower than that
of 1. Indeed, the UV–visible spectra of 2 and 3 in saline solution,
acquired at a nominal concentration of 0.1mM, showed a high
background, indicative of formation of aggregates causing light
scattering; this phenomenon was not observed for 1 under the
same conditions. To prevent aggregation, 2 and 3 were dissolved
in a buffer (0.1 M potassium phosphate, 0.1mM EDTA, pH 6.5)
containing 0.1% (v/v) Triton X-100, that is the maximum amount
of detergent that we found to not affect GST enzyme activity (buf-
fer A). Under these conditions, the solubility limit of both 2 and 3
approached 0.05mM. Thus, unless stated otherwise, in all of the
experiments, compounds 2 and 3 were dissolved in buffer A. The
molar extinction coefficients (e) of 2 and 3 were obtained by
measuring the absorbance at 430 nm of diluted standard solutions
prepared in buffer A. The calculated e were 12 500 M1 cm1 and
14 400 M1 cm1 for 2 and 3, respectively.
Compound 2 inhibits GSTP1-1 activity by 50%
We performed GSTP1-1 inhibition experiments by recording
enzyme activity in the presence of different amounts of 2 dissolved
in buffer A (pH 6.5). Surprisingly, no more than 50% of GSTP1-1
activity was inhibited by this compound with an apparent binding
affinity constant (Kiapp) of 3.9 ± 0.2 lM (Figure 1, panel A). When 1
was dissolved in buffer A, the GSTP1-1 activity was fully inhibited,
although the presence of the nonionic surfactant decreased the
affinity of 1 (Kiapp¼ 1.9 ± 0.3lM) compared to that previously
reported (0.8 ± 0.1lM)2 (Figure 1, panel B). To understand whether
the partial inhibition by 2 was due to the presence of Triton X-100,
the same experiment was performed dissolving compound 2 in a
buffer lacking the detergent (buffer B). Even if 2 was not completely
soluble in the absence of Triton X-100, the half-site inhibition pat-
tern did not change (Figure 1, panel C). Instead, the Kiapp value was
six-fold lower (0.6 ± 0.3lM). Under these conditions, compound 3
caused a complete inhibition of GSTP1-1 with a Kiapp of 0.6 ± 0.1lM
(Figure 1, panel D). Therefore, the partial inhibition of GSTP1-1 by 2
was related neither to its low water solubility, nor to the presence
of Triton X-100. HPLC evaluation of compound stability proved that,
under the assay conditions (pH 6.5 and 25 C), compounds 2 and 3
were stable up to 20min (data not shown). Therefore, we can also
rule out the possibility that the different inhibition percentages
Scheme 1. Preparation of compounds 2 and 3. (a) Benzoyl chloride, TEA, dry DCM, 0 C to rt, 22 h; (b) acetyl chloride, TEA, dry DCM, 0 C to rt, 6 h.
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obtained with the two compounds are ascribable to a different rate
of ester hydrolysis.
Compounds 1 and 2 show different spontaneous reactivity
towards GSH
In order to clarify the peculiar kinetic findings, we focused our
attention on 2. The spontaneous reactivity of 2 (20lM) towards
the nucleophile GSH (1mM) was analyzed by recording changes
in the UV–visible spectrum of the molecule at different time
points after addition of the thiol. The results were compared to
those obtained with 20 lM compound 1. In both cases, no sig-
nificant changes in the UV–visible spectrum were detected in a
1-h incubation period at 25 C and pH 6.5 (Figure 2, panel A),
as previously reported for 12. However, a remarkable reactivity
was observed when 1 was incubated with GSH at 37 C and
pH 7.4 (Figure 2, panel B). Under these conditions, the spectral
band centered at 433 nm rapidly decreased (t1/2 1 h), with a
simultaneous increase of absorbance at 350 nm. This new
optical species represents the intermediate r-complex between
1 and GSH. On the contrary, compound 2 was stable at 37 C
and pH 7.4, demonstrating that the insertion of a benzoyl moi-
ety in the side chain of 1 strongly affects the reactivity of C4
towards nucleophilic substitution reactions. A confirmation of
these results comes from HPLC analysis of incubations of com-
pound 1 or 2 (10lM) with 1mM GSH carried out at 37 C in
phosphate buffer at pH 7.4. As shown in Figure S1 (see
Supplemental material), compound 2 was relatively stable, with
less than 20% chromatographic peak area loss after 30min
(panels A and B). By contrast, compound 1 reacted rapidly
with GSH (90% peak area loss after 30min) giving rise to the
NBD S-conjugate of GSH (GS-NBD; panels A and C). No peak
corresponding to compound 1 was observed in HPLC analysis
of compound 2 incubated in phosphate buffer (pH 7.4) at
37 C up to 60min (not shown). These data indicate that com-
pound 2 is stable both to GSH-mediated thiolysis and spontan-
eous hydrolysis at pH 7.4.
Compounds 1 and 2 form different amounts of r-complex with
GSH in the presence of GSTP1-1
The next step was to analyze the reaction between 2 and GSH in the
presence of GSTP1-1, and compare these results with those obtained
with 1. The results obtained at 25 C with 1 dissolved in buffer A (pH
6.5) were in agreement with previously published data obtained in
the absence of the detergent2; the addition of GSH and GSTP1-1
caused a decrease of 80% in the absorption band centered at
433 nm. Moreover, a net increase of the absorbance was observed at
350 nm, corresponding to a band representing the r-complex inter-
mediate stabilized by the active site of GSTP1-12 (Figure 2, panel C).
It is worth mentioning that, when the reaction was followed at 37 C
and pH 7.4, the absorption band at 350 nm, which appeared imme-
diately upon GSH addition, rapidly decreased and the band at
433 nm shifted to 410–420 nm. Based on previously published data,
we can identify this new optical species as the adduct between GSH
and NBD, which absorbs at 419 nm2. Therefore, the r-complex
between GSH and 1 rapidly evolves toward GS-NBD under physio-
logical pH and temperature conditions (Figure 2, panel D). GSTP1-1
activates also compound 2 towards nucleophilic attack by GSH;
indeed, a decrease of the band at 433 nm was immediately recorded
when 2 was incubated with both GSH and GSTP1-1, at 25 C in buf-
fer A, pH 6.5 (Figure 2, panel C). However, after a 1-h incubation, the
extent of reduction was nearly half of that observed with 1, and only
a modest increase of the absorbance was observed at 350 nm.
Moreover, unlike 1, compound 2 was not affected by the increase of
Figure 1. Inhibition of GSTP1-1 by NBD derivatives. Inhibition curves of GSTP1-1 by 2 (A) or 1 (B) dissolved in buffer A (pH 6.5), at 25 C. Inhibition curves of GSTP1-1
by 2 (C) or 3 (D), dissolved in buffer B (pH 6.5), at 25 C. Data points represent the mean± SD from three independent experiments. Error bars smaller than the symbols
are not visible. Calculated Kiapp values for each condition are reported.
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pH and temperature: at 37 C and pH 7.4, the optical species at
433 nm did not shift to 410–420 nm (Figure 2, panel D), suggesting
that the r-complex between GSH and 2 is not rapidly converted
into GS-NBD.
Fluorescence spectroscopy suggests that compounds 1 and 2
have different modes of binding to GSTP1-1
Additional details of the interaction between 2 with GSTP1-1 were
obtained by fluorescence spectroscopy. We previously reported a
strong quenching of the intrinsic fluorescence of 1 upon formation
of the r-complex with GSH within the GST active site2. Here we
show that binding of GSTP1-1 to 1 quenches the emission spec-
trum of the molecule, even in the absence of GSH (Figure 3, panel
A left). However, this spectral perturbation is strongly increased
after the addition of the thiol and the subsequent formation of
the r-complex (Figure 3, panel A right), in accordance with previ-
ous findings2.
In the case of 2, a decrease in the fluorescence intensity and a
red shift (12 nm) were observed in the presence of GSH (Figure 3,
panel B right), while spectral changes were negligible in the
absence of the substrate (Figure 3, panel B left). In order to ana-
lyze protein–ligand association also by following changes in the
emission spectrum of GSTP1-1, the binding was evaluated in the
Figure 2. Evaluation of 1 and 2 reactivity with GSH in the absence or in the presence of GSTP1-1. Spectrophotometric analysis. UV–visible spectra of 20lM 1 (left) and
2 (right) dissolved in buffer A, pH 6.5, recorded at 25 C (panels A and C) or dissolved in buffer A, pH 7.4, recorded at 37 C (panels B and D), before and at different
times (0–60min) after the addition of 1mM GSH (panels A and B) or 1mM GSH and 20lM of GSTP1-1 (panels C and D).
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absence of Triton X-100 (buffer B), since the detergent absorbs in
the same spectral region of the aromatic side chains (Figure 3,
panel C). We previously reported that binding of 1 to GSTP1-1 per-
turbs the intrinsic fluorescence of the enzyme even in the absence
of GSH2; a similar behavior was observed for 2, although the
extent of fluorescence quenching was smaller in the absence of
GSH (Figure 3, panel C).
These data confirm the different mode of binding of 1 and 2
to GSTP1-1.
Co-inhibition experiments reveal that 2 does not prevent a
complete GSTP1-1 inhibition by 1
We have previously demonstrated that GSTP1-1 displays allosteric
properties11. Therefore, we investigated whether the partial
inhibition of GSTP1-1 was the result of the binding of compound 2
to one subunit, an event preventing the binding of a second inhibi-
tory species (i.e. 1) to the vacant subunit. We thus performed co-
inhibition experiments of GSTP1-1 activity by using a mixture of 1
and 2 dissolved in buffer B, pH 6.5 (Figure 4). When the amount of
2 was increased and the concentration of 1 was kept low, a partial
additive inhibitory effect was observed up to an enzyme inhibition
of approximately 50%. However, when 1 concentration was suffi-
ciently high, the compound caused a complete inhibition of the
enzyme, irrespective of the presence of 2 in the sample. Therefore,
the presence of 2 does not prevent enzyme inhibition by 1.
Figure 4. Co-inhibition experiments involving 1 and 2. Inhibition of GSTP1-1 activ-
ity was evaluated at 25 C and pH 6.5, in the presence of both 1 and 2 in a con-
centration range between 0.1 and 10lM. The substrates GSH and CDNB were
kept constant at 1mM. Data points represent the mean± SD from three inde-
pendent experiments. Error bars smaller than the symbols are not visible.
Figure 3. Spectrofluorometric analysis of the interaction between 1 or 2 and GSTP1-1. The emission spectra of (A) 1 (4lM) and (B) 2 (4lM), dissolved in buffer A (pH
6.5), were recorded at 25 C before and after the addition of increasing amounts of GSTP1-1 (1–20lM), in the absence (left) or in the presence (right) of 1mM GSH.
(C) The emission spectrum of GSTP1-1 (4lM in buffer B, pH 6.5) was recorded at 25 C before and after the addition of 2 (20lM), in the absence (left) or in the pres-
ence (right) of 1mM GSH.
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GSH is not required by 2 to decrease the interaction between
GSTP1-1 and TRAF2
We have previously shown that, in the presence of GSH, both 1 and
its analogue MC3181 strongly reduce the affinity of GSTP1-1 for
TRAF26,12. Similar results were obtained with compound 2 (Figure 5,
panel A). We have also shown that the ability of 1 to decrease the
affinity between the GSTP1-1 and TRAF2 is more evident at high lev-
els of GSH6. Surprisingly, further experiments (Figure 5, panel B)
showed that compound 2 was able to affect the formation of the
TRAF2–GSTP1-1 complex even in the absence of GSH, whilst 1 was
completely ineffective. As a control, we evaluated the occurrence of
a direct interaction between 2 and TRAF2. Addition of 2 to a solution
of TRAF2 (5 lM) did not perturb the intrinsic fluorescence of the pro-
tein, ruling out this possibility (data not shown).
Molecular docking-obtained orientations for 2 in the GSTP1-1
active site
A docking analysis was performed to determine possible structures
for the 2/GSTP1-1/GSH complex (see Supplemental Material for
protein–ligand docking conditions). Figure 6 shows two represen-
tative binding poses for 2 among the clusters with the most favor-
able binding energies. Along with an expected binding pose
similar to the crystal structure obtained for the complex of GSTP1-
1 with 1, thus lining the H-binding site of GST, the other pose
shows the NBD moiety of 2 shifted slightly deeper in the cavity
and, most importantly, with its benzoic ring placed at the interface
between the protein monomers, in close proximity with the side
chain of Tyr49. This residue is located in a loop between the a2-
helix and the b3-strand in a flexible region of the protein, and is
involved in a lock-key motif that plays a critical role in catalysis
and in the inter-subunit communication13. Furthermore, Lys102,
located in the a4-helix of the other monomer, is at less than 3 Å
from the oxygen atom of the ester function of 2, thus allowing for
a hydrogen bond formation. This interaction can strongly perturb
the relative motions of the two monomers as also supported by
normal mode analysis. Direct visualization of non-trivial modes
shows large amplitude fluctuations of the two monomers with
sliding movements of the a4-helix pivoting around Tyr49 (Figure
S2), as already established in the literature13.
Discussion
Our results show that the insertion of an aromatic ring into the
side chain of 1 strongly affects the interaction between the NBD
derivative 2 and GSTP1-1. The first difference between 1 and 2 is
Figure 6. Protein–ligand docking analysis. Two docking-obtained orientations for 2 (in medium grey); GSH is in white, residues Tyr49 from monomer A and Lys102
from monomer B are shown in sticks inside the protein surface and labeled for clarity. For comparison, the position of 1 in the crystal structure is also shown in dark
grey. Ribbon and surface representation of the remaining part of the protein is shown with subunit A (bottom, darker surface) and subunit B (top, ligther surface).
Figure 5. Effect of 1 and 2 on TRAF2–GSTP1-1 interaction. (A) His-tagged TRAF2
(0.005lM) was immobilized on Ni-NTA-coated plates and incubated with increas-
ing amounts of GSTP1-1 (from 0.1 to 8 lM) in the absence (--) or in the presence
of 8lM 1 (-w-) or 20lM 2 (-D-), and 1mM GSH. (B) The same experiment as in (A),
performed in the absence of GSH. Data points represent the mean± SD from three
independent experiments. Error bars smaller than the symbols are not visible.
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that the second compound inhibits only 50% of the enzyme
activity. One possible explanation for this finding is the occurrence
of a strong negative cooperative interaction between the two
active sites of GSTP1-1; upon the binding of 2 to the first site, this
interaction would prevent the binding of a second molecule of 2
to the vacant active site while still allowing the binding of the
substrate. This phenomenon has been already described for
GSTP1-1 interaction with other ligands, and has been interpreted
as a self-preservation mechanism that avoids the full inactivation
of the enzyme11.
Co-inhibition experiments show that 1 fully inactivates GSTP1-1
even in the presence of high 2 concentrations. This may occur
either because binding of 2 to one subunit does not hinder asso-
ciation of 1 to the other, or because 1 is able to displace 2 from
the active site by removing the strong negative cooperativity, and
allowing a complete inhibition of the enzyme by 1.
Another difference between 1 and 2 is the ability of 2 to
decrease the affinity of the TRAF2-GSTP1-1 complex even in the
absence of GSH, while 1 requires GSH to affect the TRAF2-GSTP1-1
complex. Therefore, 2 does not require GSH to affect the flexibility
of the a2-helix (residues 35–46) of GSTP1-1, which contains a
TRAF2 binding motif (TWQE)6,14, and is likely involved in the
TRAF2–GSTP1-1 interaction.
These data confirm that compounds 1 and 2 bind to the active
site of GSTP1-1 in a different fashion, in agreement with the differ-
ent spectral behavior of their complexes with GSTP1-1 (see Figures
2 and 3).
The results of the docking analysis sustain this hypothesis,
showing that one of the two representative binding poses has the
benzoyl moiety of 2 placed near the dimer interface pointing
towards Tyr49 and Lys102 of the other monomer (Figure 6). The
interaction of 2 with these residues can strongly perturb the rela-
tive motions of the two monomers of GSTP1-1, as also supported
by normal mode analysis (Figure S2). Restraint of inter-subunit
motions caused by 2 could account for long range effects in pro-
tein regions involved in the GSTP1-1 cooperativity and in the pro-
tein–protein interaction with TRAF2.
A critical aspect of most of the NBD-based GST inhibitors so far
reported is their propensity to react spontaneously with GSH9.
This may limit their clinical efficacy as the resulting GSH adduct
may be extruded from the cells by efflux pumps recognizing GSH
conjugates. It is noteworthy that the presence of a bulky benzoyl
moiety in the side chain of compound 2 confers high stability
towards the nucleophilic attack by GSH in solution, and also inhib-
its r-complex conversion into the final GS-NBD adduct in the
GSTP1-1 active site (Figure 2). The most important consequence of
the present finding is that compound 2 may serve as a lead com-
pound for the development of novel NBD derivatives not affected
in their anticancer action by fluctuations of GSH levels, and likely
characterized by increased in vivo half-life.
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